Shionogi's diversification continues with $2bn IntraBio buy
Shionogi has reached a $2bn agreement to buy Anglo-US biotech IntraBio and its recently approved Aqneursa therapy for two rare genetic disorders.
Newsletters and Deep Dive digital magazine
Shionogi has reached a $2bn agreement to buy Anglo-US biotech IntraBio and its recently approved Aqneursa therapy for two rare genetic disorders.
The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
Will your launch strategy work once it has finally left the meeting room and met the competition?
CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
Editor's Picks
Newsletters and Deep Dive
digital magazine